Key facts
- This page summarizes Roy D. Baynes's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2025, 16:05.
Roy D. Baynes - 11 Jun 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)
- Reporting relationship
- Director
- Issuer ticker
- AARD
- Reported as of
- 11 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2025, 16:05:10 UTC
- Prior SEC filing
- 19 May 2025
- Next SEC filing
- 01 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nelson Sun, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roy D. Baynes filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 13 Jun 2025.
Change
- Previous filing in this sequence was filed on 19 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001680739
Primary reporting owner
Baynes Roy D.
- Relationship
- Director
- Address
- C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO
- Signature
- /s/ Nelson Sun, as Attorney-in-Fact
- Signature date
- 13 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AARD
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +30,508
- Change %
- Price
- $0.000000
- Shares after
- 30,508
- Date
- 11 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,508
- Exercise price
- $11.29
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option shall vest in full on June 11, 2026, subject to the Reporting Person's continuous service through the vesting date, inclusive.